BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Giese-kim N, Wu M, Dehghan M, Sceats LA, Park K. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases. Am J Gastroenterol 2020;115:1698-706. [DOI: 10.14309/ajg.0000000000000750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lucas Uemura K, Sousa Freitas Queiroz N, Lees CW. What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease? Clin Gastroenterol Hepatol 2021:S1542-3565(21)00326-8. [PMID: 33727165 DOI: 10.1016/j.cgh.2021.03.016] [Reference Citation Analysis]
4 Nakase H, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Wagatsuma K, Yokoyama Y, Hisamatsu T. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research. Digestion. 2020;1-9. [PMID: 32892197 DOI: 10.1159/000510502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rosiou K, Carbonell J, Dolby V, Monfared N, Raine T, Selinger CP. Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study. Aliment Pharmacol Ther 2022. [PMID: 35611471 DOI: 10.1111/apt.17039] [Reference Citation Analysis]
6 Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. J Clin Med 2021;10:4329. [PMID: 34640345 DOI: 10.3390/jcm10194329] [Reference Citation Analysis]
7 Bourgonje AR, van Linschoten RCA, West RL, van Dijk MA, van Leer-Buter CC, Kats-Ugurlu G, Pierik MJ, Festen EAM, Weersma RK, Dijkstra G. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therap Adv Gastroenterol 2021;14:17562848211012595. [PMID: 33995584 DOI: 10.1177/17562848211012595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 An YK. Common mistakes with steroids. J Gastroenterol Hepatol 2021;36 Suppl 1:30-1. [PMID: 33817842 DOI: 10.1111/jgh.15458] [Reference Citation Analysis]
9 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignaß A, Kucharzik T; Collaborators:. [Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers]. Z Gastroenterol 2020;58:672-92. [PMID: 32659830 DOI: 10.1055/a-1193-5475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignass A, Kucharzik T; Collaborators:. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Z Gastroenterol 2020;58:982-1002. [DOI: 10.1055/a-1234-8079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Reference Citation Analysis]
12 Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm 2021;167:89-103. [PMID: 34329709 DOI: 10.1016/j.ejpb.2021.07.014] [Reference Citation Analysis]
13 Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther 2020;52:54-72. [PMID: 32348598 DOI: 10.1111/apt.15779] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 26.5] [Reference Citation Analysis]
14 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nemirovsky A, Ilan K, Lerner L, Cohen-Lavi L, Schwartz D, Goren G, Sergienko R, Greenberg D, Slonim-Nevo V, Sarid O, Friger M, Regev S, Odes S, Hertz T, Monsonego A; Israeli IBD Research Nucleus (IIRN). Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease. Brain Behav Immun Health 2022;19:100407. [PMID: 35024638 DOI: 10.1016/j.bbih.2021.100407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gomollón F. Inflammatory bowel disease and corticosteroids: the first RCT. Nat Rev Gastroenterol Hepatol 2021;18:833. [PMID: 34545242 DOI: 10.1038/s41575-021-00524-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
18 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. IJMS 2022;23:6966. [DOI: 10.3390/ijms23136966] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]